Lynparza Combo Approved for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Lynparza is a poly polymerase inhibitor.
Men’s Health Update
MEN’S HEALTH UPDATE
Adding Talazoparib to Enzalutamide Appears Beneficial in mCRPC With HRR Mutations
Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests.
PSA Nadir After RT+ADT for Prostate Cancer Predicts Outcomes
New findings could have a role in conducting clinical trials of novel systemic therapies.
PSMA-Targeted Imaging Agent Posluma Approved to Aid in Prostate Cancer Detection
The approval was based on data from the LIGHTHOUSE and SPOTLIGHT clinical trials.
Transient Benefit in Outcomes Seen With Androgen Suppression + RT for Prostate Cancer
Transient clinically meaningful decline noted in EPIC hormonal and sexual domains with total androgen suppression added to radiation
FDA Grants Full Approval to Paxlovid to Treat COVID-19
Paxlovid has been taken by seniors and others at high risk for severe COVID-19 under an emergency use approval
Second-Generation Antiandrogens Up Risk for Cognitive, Functional Toxic Effects
The increasing number of indications for second-generation antiandrogens may result in a large group of men at risk for toxic effects, according to investigators.
Real-World mCSPC First-Line Treatment Intensification Remains Low
Study findings highlight the need for earlier mCSPC treatment intensification by urologists and oncologists.
Many Older Americans Would Like to Take Fewer Meds, Poll Reveals
Older Americans think they take too many medicines, and a sizable percentage said they have cut back
Changes in Cancer Risk Factors, Screening Reported During Pandemic
Declines seen in current smoking, physical inactivity, heavy alcohol consumption; increase seen in uptake of HPV vaccine, stool testing for CRC
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Men's Health Update
Loading... 
Loading...